The effectiveness of PD-1 and PD-L1 inhibitors depends on patients' characteristics, such as (i) gender, (ii) types of tumors, (iii) mutation, translocation of genes (EGFR, Kras, ALK), and (iv) metastases of tumor (D'Incecco et al., 2015). The gene discussed is CD274; the disease is neoplasm.